Status:
COMPLETED
Investigating Healthcare Disparities in Vitiligo
Lead Sponsor:
Momentum Data
Collaborating Sponsors:
Pfizer
Conditions:
Vitiligo
Eligibility:
All Genders
Up to 95 years
Brief Summary
Vitiligo is an acquired, non contagious skin disorder characterised by depigmented patches of skin that may appear in a localised or very generalised distribution, and affecting 0.5-2.0% of the global...
Detailed Description
This study will provide estimate of the cumulative lifetime risk of vitiligo in the population overall, and by important sociodemographic groups, including age, sex, ethnicity and deprivation, which w...
Eligibility Criteria
Inclusion
- The cohort for the endpoint analysis will consist of all adults and adolescents (aged 13+) contributing to OPCRD during the study period (2004-2020).
- The cohort for the lifetime risk analysis will consist of all people contributing to OPCRD during the study period.
- The vitiligo cohort consists of people newly diagnosed with vitiligo at any point during the study period.
Exclusion
- People with the alternative non-vitiligo diagnoses (other hypopigmenting conditions).
- People with vitiligo diagnosis within 6 months of practice registration.
- People without vitiligo with less than 1 year of follow up within the dataset.
- People over the age of 95 (for those reaching age 95 during the follow up period follow up was censored at age 95).
- People who have opted out of record sharing.
Key Trial Info
Start Date :
July 20 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 17 2024
Estimated Enrollment :
39374 Patients enrolled
Trial Details
Trial ID
NCT06097494
Start Date
July 20 2023
End Date
July 17 2024
Last Update
March 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Momentum Data Limited
London, United Kingdom